4 ms·
I don't think we'd have 99% of these novel clinical compounds if it weren't for patents. As for approvals, I don't know why we have each country doing its own
by Scoundreller 8y ago
I don't think we'd have 99% of these novel clinical compounds if it weren't for patents.
As for approvals, I don't know why we have each country doing its own approvals, instead of international groups that individuals can choose whether they want to trust or not. Are Europeans sufficiently different than Chinese, Indians, Australians, Canadians, Germans or Americans to warrant independent safety approvals?
If they're using different metrics to process approvals, why? Shouldn't the same inputs result in the same outputs?
- spectrum1234 8y agoWhy wouldn't these compounds evolve to be open source? Barriers to entry wouldn't be billions in R&D if every stepping stone was open sourced.
- pkaye 8y agoThe real question is who will pay for testing drug safety and efficacy. Take Auryxia which is literally ferric citrate. Its used by kidney patients to control phosphorus levels and boost iron. Why did it take so long to get tested and approved as a drug when the formula was "open source" for a long time? Well one company did the time and effort and suddenly it is considered a valuable drug. The value came from proving the safety and efficacy and someone has to be willing to fund it.
- Retric 8y agoDrug tests are not inherently that expensive. FDA trials run about 1% of the cost of each new drug. https://www.jhsph.edu/news/news-releases/2018/cost-of-clinical-trials-for-new-drug-FDA-approval-are-fraction-of-total-tab.html https://www.jhsph.edu/news/news-releases/2018/cost-of-clinic... The long line of failed drugs are the real issue.
- refurb 8y agoNo offense but the article you referenced is misleading. Sure, just the trial might cost that little if it’s an orphan disease, but it’s also ignoring all the other stuff that goes along with running a trial. Things like manufacturing, compliance, data analysis, etc. When you look at the total cost of R&D for a drug, it’s typically 1/3 for discovery and 2/3 for development (clinical trials). If your drug is used in any reasonable sized population, development is easily in the hundreds of millions of dollars. You are correct about the failure rates though.
- BurningFrog 8y agoIf approvals were about science, one approval would be good enough worldwide. In reality, approvals are also about politics.
- refurb 8y agoWell, considering the US avoided the thalidomide tragedy because they decided approval in Europe was t good enough, you’re unlikely to see a scenario where it gets approved simply because someone else approved it.
- baud147258 8y agoThe thalidomide tragedy didn't happen in France too, because of a new law adding stricter controls on drugs.